European CHMP recommends approval of generic insulin aspart (Insulin aspart Sanofi) for the treatment of diabetes mellitus

Insulin aspart Sanofi is a biosimilar medicinal product. Data show that it has comparable quality, safety and efficacy to the reference product NovoRapid (insulin aspart), and it is intended to be licensed for the same indication.


European Medicines Agency